Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
Completed
Oakwood Laboratories, LLC
Phase 3
2007-04-01
The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for
Injectable Suspension 22.5 mg in reducing serum testosterone to castrate levels in patients
with prostate cancer.
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Completed
Colorado Center for Reproductive Medicine
Phase 4
2003-03-01
This prospective randomized trial evaluates whether one can predict which infertile women
with endometriosis who are candidates for in vitro fertilization will benefit from prolonged
therapy with a GnRH agonist by the determination of the absence of endometrial expression of
the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which
all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for
in vitro fertilization and then undergo randomization to a three month course of a depot
preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian
stimulation or standard therapy. prio
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
Completed
Tolmar Inc.
Phase 3
2015-08-31
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension
for treatment of children with Central Precocious Puberty.
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Active, not recruiting
Myovant Sciences GmbH
Phase 3
2017-04-18
The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams
(mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate
levels (< 50 nanograms/deciliter [ng/dL]) in participants with androgen-sensitive advanced
prostate cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
